Drug therapy of heart failure: an immunologic view.
暂无分享,去创建一个
[1] C. Stefanadis,et al. The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule? , 2010, Current vascular pharmacology.
[2] N. Turner,et al. Cardiac fibroblasts: at the heart of myocardial remodeling. , 2009, Pharmacology & therapeutics.
[3] Yong Chen,et al. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. , 2009, Journal of cardiac failure.
[4] P. Kotyla. Atorvastatin pleiotropic effects mediated via suppression of TNF-alpha in congestive heart failure patients with initial normal TNF-alpha levels. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] T. Balakhonova,et al. [The study of peculiarities of immunotropic action of statins in chronic heart failure of various etiology]. , 2009, Kardiologiia.
[6] L. Waldbeser,et al. Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines , 2008, Inflammation Research.
[7] Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[8] J. Avorn,et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. , 2008, American heart journal.
[9] T. Kurtz,et al. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? , 2008, Journal of hypertension.
[10] E. Tatlı,et al. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure. , 2008, International journal of cardiology.
[11] S. Anker,et al. The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond. , 2008, Heart failure clinics.
[12] P. Ponikowski,et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial , 2008, The Lancet.
[13] Carlos Orrego,et al. Cytokines and acute heart failure , 2008, Critical care medicine.
[14] M. Hino,et al. Calcium channel blockers suppress cytokine-induced activation of human neutrophils. , 2008, American journal of hypertension.
[15] D. Mikhailidis,et al. Should a statin be prescribed to every patient with heart failure? , 2008, Heart Failure Reviews.
[16] A. Jánosi,et al. Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.
[17] P. Poole‐Wilson,et al. Altered intestinal function in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.
[18] E. Czarnecka,et al. Influence of enalapril, quinapril and losartan on lipopolysaccharide (LPS)-induced serum concentrations of TNF-alpha, IL-1 beta, IL-6 in spontaneously hypertensive rats (SHR). , 2007, Pharmacological reports : PR.
[19] R. Fernandez-Botran,et al. Digoxin-like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. , 2007, Clinical chemistry.
[20] K. Gong,et al. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches , 2007, International journal of clinical practice.
[21] C. Stefanadis,et al. Statins in heart failure. Beyond the lipid lowering effect. , 2007, International journal of cardiology.
[22] Q. Han,et al. Phenylarsine oxide inhibited beta-adrenergic receptor-mediated IL-6 secretion: inhibition of cAMP accumulation and CREB activation in cardiac fibroblasts. , 2007, Biochemical and biophysical research communications.
[23] R. Weiss,et al. Novel Effect of Mineralocorticoid Receptor Antagonism to Reduce Proinflammatory Cytokines and Hypothalamic Activation in Rats With Ischemia-Induced Heart Failure , 2006, Circulation Research.
[24] B. Li,et al. Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. , 2006, International journal of cardiology.
[25] C. White,et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. , 2006, Journal of cardiac failure.
[26] P. Singal,et al. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. , 2006, American journal of physiology. Heart and circulatory physiology.
[27] J. Cleland,et al. Threats, opportunities, and statins in the modern management of heart failure. , 2006, European heart journal.
[28] H. Morita,et al. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. , 2006, Journal of pharmacological sciences.
[29] K. Gong,et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. , 2006, American heart journal.
[30] S. Gabriel,et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[31] J. McMurray,et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics , 2005, European journal of heart failure.
[32] C. Hengstenberg,et al. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. , 2005, International journal of cardiology.
[33] L. Ulloa. The vagus nerve and the nicotinic anti-inflammatory pathway , 2005, Nature Reviews Drug Discovery.
[34] G. Torre-Amione. Immune activation in chronic heart failure. , 2005, The American journal of cardiology.
[35] M. Hudson,et al. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. , 2005, Rheumatology.
[36] E. Tatlı,et al. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. , 2005, The Canadian journal of cardiology.
[37] B. Greenberg,et al. IL-1β and TNF-α upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart , 2005 .
[38] S. Gabriel,et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. , 2005, Arthritis and rheumatism.
[39] L. Monassier,et al. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts , 2018 .
[40] D. Mann,et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. , 2004, Cardiovascular research.
[41] H. Crijns,et al. Aldosterone levels after angiotensin receptor blocker treatment. , 2004, Circulation.
[42] Stephan von Haehling,et al. Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.
[43] T. MacDonald,et al. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. , 2004, Cardiovascular research.
[44] F. Wolfe,et al. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. , 2004, The American journal of medicine.
[45] K. Bendtzen,et al. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. , 2004, Immunology letters.
[46] K. Asadullah,et al. Molecular mechanisms of interleukin‐10‐mediated inhibition of NF‐κB activity: a role for p50 , 2004, Clinical and experimental immunology.
[47] V. Petrov,et al. Collagen production in cardiac fibroblasts during inhibition of angiotensin-converting enzyme and aminopeptidases. , 2004 .
[48] H. Zimmer,et al. Regulation of norepinephrine-induced proliferation in cardiac fibroblasts by interleukin-6 and p42/p44 mitogen activated protein kinase , 2004, Molecular and Cellular Biochemistry.
[49] J. Cohn,et al. Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure: Results From the Valsartan Heart Failure Trial , 2003, Circulation.
[50] S. Rajagopalan,et al. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease , 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[51] D. Mann,et al. Activation and Functional Significance of the Renin-Angiotensin System in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor , 2003, Circulation.
[52] K. Weber,et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. , 2003, American journal of physiology. Heart and circulatory physiology.
[53] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[54] G. Francis,et al. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? , 2003, Journal of the American College of Cardiology.
[55] R. Weiss,et al. Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.
[56] O. Chassany,et al. Defining the Role of Calcium Channel Antagonists in Heart Failure Due to Systolic Dysfunction , 2003, American Journal of Cardiovascular Drugs.
[57] Kevin J. Tracey,et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation , 2002, Nature.
[58] B. Greenberg,et al. Molecular Medicine Tumor Necrosis Factor-�–Induced AT 1 Receptor Upregulation Enhances Angiotensin II–Mediated Cardiac Fibroblast Responses That Favor Fibrosis , 2022 .
[59] Douglas L Mann,et al. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.
[60] A. Struthers. Aldosterone: cardiovascular assault. , 2002, American heart journal.
[61] J. Kjekshus,et al. Inflammatory imbalance between IL‐10 and TNFα in unstable angina potential plaque stabilizing effects of IL‐10 , 2002, European journal of clinical investigation.
[62] C. Vrints,et al. Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. , 2002, International journal of cardiology.
[63] D. Mann,et al. Angiotensin II Induces Tumor Necrosis Factor Biosynthesis in the Adult Mammalian Heart Through a Protein Kinase C-Dependent Pathway , 2002, Circulation.
[64] S. Hosoda,et al. Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. , 2002, Journal of cardiology.
[65] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[66] S. Fichtlscherer,et al. Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients With Advanced Heart Failure , 2001, Circulation.
[67] D. Oral,et al. Effect of Losartan on Circulating TNFα Levels and Left Ventricular Systolic Performance in Patients with Heart Failure , 2001 .
[68] S. Adamopoulos,et al. A glossary of circulating cytokines in chronic heart failure , 2001, European journal of heart failure.
[69] S. Anker,et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. , 2001, Cytokine.
[70] M. Kinoshita,et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. , 2001, Journal of the American College of Cardiology.
[71] G. Francis,et al. Pathophysiology of chronic heart failure. , 2001, The American journal of medicine.
[72] J. Kjekshus,et al. Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). , 2001, American heart journal.
[73] F. Luft,et al. Workshop: mechanisms and cardiovascular damage in hypertension. , 2001, Hypertension.
[74] S. Zhao,et al. Captopril inhibits the production of tumor necrosis factor-alpha by human mononuclear cells in patients with congestive heart failure. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[75] G. Chrousos,et al. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. , 2000, Pharmacological reviews.
[76] K. Tracey,et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin , 2000, Nature.
[77] M. Kinoshita,et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.
[78] S. Frøland,et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. , 1999, Journal of the American College of Cardiology.
[79] W. Paulus. How are cytokines activated in heart failure? , 1999, European journal of heart failure.
[80] A. Matsumori,et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. , 1999, Japanese circulation journal.
[81] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[82] B. Greenberg,et al. Tumor Necrosis Factor- (cid:97) Upregulates Angiotensin II Type 1 Receptors on Cardiac Fibroblasts , 1999 .
[83] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[84] M. Netea,et al. The effect of renin–angiotensin system inhibitors on pro‐ and anti‐inflammatory cytokine production , 1998, Immunology.
[85] R. Pacher,et al. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[86] D. Furst. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. , 1997, British journal of rheumatology.
[87] A. Matsumori,et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. , 1997, Circulation.
[88] J. A. Bowers,et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. , 1997, Journal of the American College of Cardiology.
[89] J. Satoh,et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-α in vitro and in vivo , 1997 .
[90] J. Egido,et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.
[91] W. Remme,et al. Value of digoxin in heart failure and sinus rhythm: new features of an old drug? , 1996, Journal of the American College of Cardiology.
[92] A. Matsumori,et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. , 1994, British heart journal.
[93] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[94] K. Swedberg,et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.
[95] H. Besedovsky,et al. Neuroendocrine, sympathetic and metabolic responses induced by interleukin-1. , 1989, Neuroendocrinology.
[96] P. Korner,et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.
[97] J. Staessen,et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.